Vpriv Injection, Powder, Lyophilized, For Solution
NDC 54092-701
Product Information
Vpriv (velaglucerase alfa) is a BLA-approved product labeled by Takeda Pharmaceuticals America, Inc.. Velaglucerase is used to treat a certain rare genetic problem (Gaucher disease). It is supplied as a injection, powder, lyophilized, for solution for intravenous administration. This product entry covers the primary NDC 54092-701 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 54092-701?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- VELAGLUCERASE ALFA (UNII: 23HYE36B0I)
- VELAGLUCERASE ALFA (UNII: 23HYE36B0I) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
- POLYSORBATE 20 (UNII: 7T1F30V5YH)
- TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)
- SUCROSE (UNII: C151H8M554)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 901808 - velaglucerase alfa 400 UNT Injection
- RxCUI: 901812 - VPRIV 400 UNT Injection
- RxCUI: 901812 - velaglucerase alfa 400 UNT Injection [Vpriv]
- RxCUI: 901812 - Vpriv 400 UNT Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.